I am honored to testify in these hearings on “Medicaid Prescription Drugs: Examining Options for Payment Reform,” held by the Committee on Energy and Commerce’s Subcommittee on Health. I am a Resident ...
Unintended consequences of health policy legislation could affect cancer care delivery. While offering a blunt approach to cost containment, site-neutrality legislation risks reducing access to care ...
Hospitals can leverage their position between the ultimate buyers and sellers of drugs to retain a substantial share of insurer pharmaceutical expenditures. In this study, we used 2020–2021 national ...
The Centers for Medicare & Medicaid Services (“CMS”) has finalized and proposed several significant changes affecting both site neutrality in Medicare payments and the 340B Drug Pricing Program. These ...
Recent court rulings have thrust the 340B Drug Pricing Program back in the headlines, and it is worth examining some of the lesser-known aspects of how this program interacts with state and federal ...
In its slogan, BeiGene says that “cancer has no borders.” It’s a different story in Europe, however, where the influence of multiple regulatory agencies and discrete reimbursement processes can turn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results